Ⅰ-单克隆抗体对人卵巢癌细胞株OC-3-VGH裸鼠皮下移植瘤的抑制作用

目的： 探索131I-单克隆抗体对人OC-3-VGH卵巢癌裸鼠肿瘤的抑制作用。方法：建立人卵巢癌裸鼠皮下移植瘤模型，将28只移植瘤模型裸鼠随机分成7组，即阴性对照组 (等体积生理盐水)、60 mg/kg环磷酰胺 (cyclophosphamide，CP)阳性组、单抗高 (10 mg/kg)、低 (2 mg/kg)剂量组、131I-单抗高剂量组 (10 mg/kg＋125 μCi)、131I-单抗中剂量组 (6 mg/kg＋75 μCi)、131I-单抗低剂量组 (2 mg/kg＋25 μCi)，各组连续腹腔给药14 d，分别在第0天 (d0)、d4、d8、d12、d15称量裸鼠体质量，测量肿瘤体积，于末次给药后24 h，剖瘤称取质量，计算相对肿瘤增殖率和抑瘤率。结果：与阴性对照组相比，单抗高剂量组、131I-单抗中、高剂量组均显著抑制肿瘤生长，相对肿瘤增殖率分别是54%、48%、30%，抑瘤率分别为33.59%、45.80%、64.89%，差异均具有统计学意义 (P＜0.01)，单抗高剂量组与131I-单抗高剂量组间的差异也具有统计学意义 (P＜0.05)。结论：单克隆抗体和131I-单克隆抗体对人OC-3-VGH卵巢癌均有明显的抑制作用，131I-单克隆抗体高剂量组有明显的增效作用。

Inhibitory effect of 131I-monoclonal antibody on subcutaneously transplanted human ovarian cancer cell line OC-3-VGH tumor

OBJECTIVE: To explore the inhibitory effect of 131I-monoclonal antibody on tumor growth of human ovarian cancer cell line OC-3-VGH in nude mice. METHODS：The transplanted human ovarian carcinoma model was established by subcutaneous injection of OC-3-VGH cells in nude mice. The mice were randomly divided into negative control group，CP positive control group (60 mg/kg)，high dose (10 mg/kg)，low dose (2 mg/kg) group of monoclonal antibody，high dose (10 mg/kg＋125 μCi)，medium dose (6 mg/kg＋75 μCi)，low dose (2 mg/kg＋25 μCi) group of 131I- monoclonal antibody. Seven groups received continuously intraperitoneal injection for 14 d. Diameters of tumors were measured and nude mice were weighed on d0，d4，d8，d12，d15. The animals were killed 24 h after the last treatment. The transplanted tumors were weighed，the inhibitory rate and treatment over control growth ratios were calculated. RESULTS：The high dose monoclonal antibody group，and medium and high dose 131I-monoclonal antibody groups had significant tumor inhibiting effects in vivo，with treatment over control growth ratios of 54%，48%，30% and inhibitory rates of 33.59%，45.80% and 64.89%，respectively. Compared with the negative control，there was significant difference(P＜0.01) . The high dose monoclonal antibody group was compared with the high dose 131I-monoclonal antibody group，showing a statistical difference (P＜0.05). CONCLUSION： Both monoclonal antibody and 131I- monoclonal antibody groups effectively inhibited the growth of human ovarian carcinoma in vivo. The therapeutic efficiency was enhanced significantly in the high dose 131I-monoclonal antibody group.